ERS Highlights

Rolof Gijtenbeek, ERS 2021: The NVALT 17 Study

We were delighted to talk with Dr Rolof Gijtenbeek (Medical Center Leeuwarden, Leeuwarden, The Netherlands) around his abstract on ‘Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.‘, (Presentation ID 4324) which was presented at […]

Sleep Related Breathing Disorders

Jan Hedner, ERS 2021: Sulthiame for Moderate to Severe Obstructive Sleep Apnoea

We were delighted to talk with Professor Jan Hedner (The University of Gothenburg, Gothenburg, Sweden) around the rationale, and safety and efficacy findings of using sulthiame in moderate to severe obstructive sleep apnoea. The abstract ‘Safety and efficacy of sulthiame in moderate to severe obstructive sleep apnea: a randomized placebo-controlled parallel-group trial’ (Presentation ID 4383) […]

Cystic Fibrosis

Molla Imaduddin Ahmed, ERS 2021: Tezacaftor/Ivacaftor Effect on Exercise Capacity in Adolescents with Cystic Fibrosis

It was a pleasure to speak with Dr Molla Imaduddin Ahmed (Leicester Childrens’ Hospital, Leicester, UK) around his abstract on ‘The impact of Symkevi (Tezacaftor/Ivacaftor) on exercise capacity in adolescents with CF.‘, which was presented at ERS International Congress 2021, 5-8 September 2021. Questions How useful is exercise capacity as a clinical endpoint for cystic […]

Cystic Fibrosis

Molla Imaduddin Ahmed, ERS 2021: Advances in the Treatment of Cystic Fibrosis

It was great to talk with Dr Molla Imaduddin Ahmed (Leicester Childrens’ Hospital, Leicester, UK) around the impact of CFTR modulator therapies and exciting advances in the treatment of cystic fibrosis. Questions What has been the impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies on the treatment of cystic fibrosis (CF)? (0:20) What […]

Chronic Cough

Peter Dicpinigaitis, ERS 2021: Unmet Needs and Advances in Chronic Cough

TouchRESPIRATORY got the opportunity to catch up with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to learn more about the unmet needs in chronic cough and recent clinical advances. Questions What are the unmet needs in the treatment of patients with refractory or unexplained chronic cough (RCC or […]

Chronic Cough

Peter Dicpinigaitis, ERS 2021: Gefapixant for Chronic Cough

It was a pleasure to meet with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to discuss the findings from the COUGH-1 and COUGH-2 studies, investigating gefapixant for the treatment of patients with chronic cough. The abstract ‘Patient-reported chronic cough severity over 52 weeks in two phase 3 trials […]

Idiopathic pulmonary fibrosis

Vincent Cottin, ERS 2021: Challenges and Latest Research in Idiopathic Pulmonary Fibrosis

We were delighted to catch up with Professor Vincent Cottin (National Reference Centre for Rare Pulmonary Diseases, Lyon, France) to discuss the challenges associated with investigating rare diseases and the hot topics in idiopathic pulmonary fibrosis. Questions What are the challenges associated with clinical trials investigating rare diseases such as idiopathic pulmonary fibrosis (IPF)? (0:20) […]

Idiopathic pulmonary fibrosis

Vincent Cottin, ERS 2021: GLPG1205 for Idiopathic Pulmonary Fibrosis

Professor Vincent Cottin (National Reference Centre for Rare Pulmonary Diseases, Lyon, France) spoke with touchRESPIRATORY around the Phase 2 PINTA study, investigating GLPG1205 for idiopathic pulmonary fibrosis. The abstract ‘Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA).’ (Presentation ID 2904) was presented at ERS International Congress 2021, 5-8 September 2021. […]

Interventional Pulmonology

Alan Kirk, ERS 2021: The TRANSFORM Study – A 24-month Follow-up

We were delighted to catch up with Mr Alan Kirk (Golden Jubilee National Hospital, West Dunbartonshire, Scotland, UK) to discuss the 24-month follow-up to the TRANSFORM study, investigating endobronchial valve treatment for patients with severe heterogeneous emphysema. The abstract ‘Durability of Zephyr Valve treatment: 24-month follow-up in the TRANSFORM Study.‘ (Presentation ID: 1201) was presented at […]

FILTER YOUR SEARCH

Speciality: